United Therapeutics authorized up to $2.0 billion to buy its own shares, creating a way to return cash and potentially support its shares. The filing reports permission to buy, not completed purchases.
The plan gives the company a way to return cash and may reduce the number of shares over time. The filing only authorizes purchases, so this benefit depends on whether the company uses the program.
Follow United Therapeutics Corporation (UTHR) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for UTHR